Synairgen Presents In Vitro Potency Data for Interferon Beta Against SARS-CoV-2 Variants and Lung Antiviral Biomarker Data for Inhaled SNG001 at the 8th ESWI Influenza Conference

/PRNewswire/ -- Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral...

Related Keywords

United Kingdom ,Wuhan ,Hubei ,China ,Geoff Nash ,Mary Conway ,Richard Marsden ,John Ward ,Donna Davies ,Duncan Monteith ,Brooke Clarke ,James Black ,Jessica Hodgson ,Mary Jane Elliott ,Ratko Djukanovic ,Kate Bannatyne ,Freddie Barnfield ,Lucy Featherstone ,Numis Securities Limited Joint Broker ,Head Of Communications ,United Kingdom National Institute For Health Research ,Drug Administration ,Consilium Strategic Communications Financial Media ,European Scientific Working Group In Influenza ,University Of Southampton Professors Sir Stephen Holgate ,Mkc Strategies Llc Us Media Relations ,Urgent Public Health ,European Scientific Working Group ,Influenza Conference ,Synairgen Chief Scientific Officer ,Chief Executive Officer ,Chief Financial Officer ,Joint Broker ,Charlie Beeson ,Corporate Finance ,Sunil De Silva ,Securities Limited ,Strategic Communications ,Financial Media ,Investor Relations ,Jane Elliott ,United Kingdom Based ,Fast Track ,National Institute ,Health Research ,Southampton Professors Sir Stephen Holgate ,Synairgen Plc ,